BA

Bayer

Every trial this sponsor leads in the registry, and everything it has published.

1,191All trials
Recruiting35
Recruited21
Not yet recruiting10
Completed1,013
Stopped112

66 active · 6% of this sponsor’s registry footprint

Oncology27 trials
Cardiovascular13 trials
Metabolic/Endocrine/Nutrition7 trials
Neurology6 trials
Renal & Urology4 trials
Womens Health2 trials
Haematology1 trial
Infectious Disease1 trial

Not shown above: 1 Phase 1 healthy-volunteer trial and 3 trials whose condition matched no therapy area.

Trials by phase

Phase 1378
Phase 2243
Phase 3317
Phase 4110
Unphased143

Pipeline by phase · 33 drugs in active development

Phase 3 · 6 drugs

Finerenone11 trials · 7 recruitingest. Sept 2026
Sevabertinib (BAY2927088)2 trials · 2 recruitingest. Oct 2027
BAY37231131 trial
bemdaneprocel1 trial · 1 recruitingest. Mar 2027
Elinzanetant1 trial
Riociguat1 trial

Phase 2 · 5 drugs

AB-10052 trialsest. Apr 2028
AAV2-GDNF gene therapy1 trial · 1 recruitingest. Aug 2028
AB-10021 trialest. Oct 2026
BAY 34010161 trial · 1 recruitingest. Nov 2027
Regorafenib1 trialest. Apr 2028

Phase 1 · 19 drugs

225Ac-PSMA-Trillium (BAY3563254)1 trial · 1 recruitingest. Nov 2028
AB-1003 dose level 11 trialest. Dec 2028
AB-1009 (GAA Gene)1 trial · 1 recruitingest. Sept 2028
Aspirin1 trial · 1 recruitingest. Nov 2026
BAY 35479261 trial · 1 recruitingest. Jul 2029
BAY 37133721 trial · 1 recruitingest. Jun 2029
BAY 37712491 trial · 1 recruitingest. Jul 2029

Phase 4 · 3 drugs

Darolutamide5 trials · 2 recruitingest. Apr 2027
Acoramidis3 trials · 2 recruitingest. Jul 2027

Not counted above: 2 unphased interventions.

Active trials only, code names and brands merged. 1,013 completed trials are in the counts above but their drugs are not folded into this pipeline.

Disease landscapes · 3 of 10 curated

Type 2 diabetes (Endocrinology)6 trials · 3 recruiting · 1 drug0.6% of landscape
Non-small cell lung cancer (Oncology)3 trials · 1 recruiting · 3 drugs0.2% of landscape
Breast cancer (Oncology)2 trials · 1 recruiting · 2 drugs0.1% of landscape

Active trials judged against ten curated disease boundaries; the share compares this company's active trials with the landscape's industry-wide total. Activity outside these landscapes appears in the therapy-area split above.

Track your drug now for free

We check every one of its trials daily and tell you what moved.

  • Status changeStatus moved to completedWas recruiting · always alerts
  • Completion date movePrimary completion slipped 210 daysSlips and pull-ins of 30+ days
  • New trialNew trial registered in your scopeFirst posted within 30 days
  • Enrollment changeEnrollment grew to 1,200Moves of 15%+ or count finalised
  • Substantive record editPrimary endpoint redefined from 24 to 52 weeksRead overnight and flagged in plain English
US registryClinicalTrials.gov
EU registryCTIS · Soon